title: [Assessment of curative effect on erectile dysfunction of two drugs].
abstract: OBJECTIVE
  To further discuss the method of evaluating curative effect on erectile dysfunction(ED).
  
  
  METHODS
  Clinical trials(Phase II) of sildenafil and phentolamine were both 8-week-long, randomized, double-blind and placebo-controlled. Not only the curative effect between each treatment group and placebo group but also between the treatment groups were compared. The dosage of sildenafil and phentolamine was respectively 50-100 mg and 40 mg.
  
  
  RESULTS
  Efficiency, success rate of sexual intercourse and general curative effect in sildenafil and phentolamine groups were respectively 79.17%, 75.00%, 83.33% and 52.38%, 85.71%, 52.38%. The result revealed a statistically significant (P < 0.05) improvement over placebo. But no obvious differences were shown between the two treatment groups(P > 0.05).
  
  
  CONCLUSIONS
  Most assessments of curative effect of ED drugs come from questionnaires answered subjectively by patients. The Lack of objective assessment criteria way lead to the non-conformity between trial results and clinical practices. So the curative effect of drugs shall be assessed more accurately and from more perspectives.
authors.affiliation: Department of Sexual Medicine, No 402 Hospital, Ministry of Electronic Industry, Beijing 100039, China.
authors.forename: Da-Zhong
authors.initials: DZ
authors.lastname: Yang
authors.forename: Xiao-Nian
authors.initials: XN
authors.lastname: Ma
authors.forename: Zuo-Jun
authors.initials: ZJ
authors.lastname: Yu
authors.forename: Yu
authors.initials: Y
authors.lastname: Jiao
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010646:Phentolamine / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000317:Adrenergic alpha-Antagonists; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D010646:Phentolamine